<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ERYTHROMYCIN ETHYLSUCCINATE</span><br/>(er-ith-roe-mye'sin)<br/><span class="topboxtradename">Apo-Erythro-ES <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">E.E.S., </span><span class="topboxtradename">E.E.S.-200, </span><span class="topboxtradename">E.E.S.-400, </span><span class="topboxtradename">EryPed, </span><span class="topboxtradename">Pediamycin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">macrolide antibiotic</span><br/><b>Prototype: </b>Erythromycin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg chewable tablet, 400 mg tablets; 100 mg/2.5 mL, 200 mg/5 mL, 400 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Acid-stable ester salt of erythromycin.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>More active against gram-positive than gram-negative bacteria. Effectiveness against <i>Chlamydia trachomatis</i> is basis for its topical use in prophylaxis of neonatal inclusion conjunctivitis.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>See erythromycin.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to erythromycins; history of erythromycin-associated hepatitis; preexisting liver disease.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Myasthenia gravis; pregnancy (category B), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Infection</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg q6h up to 4 g/d according to severity of infection<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 3050 mg/kg/d in 4 divided doses (max: 100 mg/kg/d) for severe infections<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: 400 mg erythromycin ethylsuccinate is approximately equal to 250 mg erythromycin base.
            			
         </li>
</ul><span class="adminroutetype">Oral</span><br/><ul>
<li>Chewable tablets should be chewed and not swallowed whole.</li>
<li>Suspensions are stable for 14 d at room temperature unless otherwise stated by manufacturer. Note expiration date.</li>
<li>Store tablets in tight containers unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Diarrhea, <span class="speceff-common">nausea,</span> vomiting, stomatitis, <span class="speceff-common">abdominal cramps,</span> anorexia, hepatotoxicity. <span class="typehead">Skin:</span> Skin eruptions. <span class="typehead">Special Senses:</span> Ototoxicity. <span class="typehead">Body as a Whole:</span> Potential for superinfections. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Serum levels and toxicities of <b>alfentanil,</b>
<b>bexarotene,</b>
<b>carbamazepine,</b>
<b>cevimeline,</b>
<b>cilostazol,</b>
<b>clozapine,</b>
<b>cyclosporine,</b>
<b>disopyramide,</b>
<b>estazolam,</b>
<b>fentanyl,</b>
<b>midazolam,</b>
<b>methadone,</b>
<b>modafinil,</b>
<b>quinidine,</b>
<b>sirolimus,</b>
<b>digoxin,</b>
<b>theophylline,</b>
<b>triazolam,</b>
<b>warfarin</b> are increased. <b>Ergotamine</b> may increase peripheral vasospasm. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Concentrates in liver; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in bile and feces. <span class="typehead">Half-Life:</span> 25 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Determine C&amp;S prior to treatment. Periodic liver function tests and blood cell counts if therapy is prolonged 10
            d.
         </li>
<li>Cholestatic hepatitis syndrome is most likely to occur in adults who have received erythromycin estolate for &gt;10 d or who
            have had repeated courses of therapy. The condition generally clears within 35 d after cessation of therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Advise patient to report immediately the onset of adverse reactions and to be on the alert for signs and symptoms associated
            with jaundice (see Appendix F).
         </li>
<li>Ototoxicity is most likely to occur in patients receiving high dosage or who have impaired kidney function. Report immediately
            the onset of tinnitus, vertigo, or hearing impairment.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>